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Prosthesis size and prosthesis-
patient size are unrelated to
prosthesis-patient mismatch
To the Editor:
We read with interest the report of Black-
stone and colleagues1 published in the Sep-
tember 2003 issue of the Journal, as well as
the editorial of Gillinov and coworkers2 in
the August 2003 issue. The implicit con-
clusion of these two articles was that pros-
thesis-patient mismatch (PPM) is a rare
occurrence after aortic valve replacement
and that it has a negligible impact with
regard to postoperative outcomes. To de-
fine PPM and analyze its consequences,
both sets of authors chose, however, to use
an indexed area based on the internal geo-
metric dimension of the prosthesis divided
by the patient’s body surface area, rather
than the indexed effective orifice area,
which is the physiologic parameter most
often used to define PPM. They justified
their choice of parameter on the basis that
geometric measures “are determined before
implantation, have much less variability,
and are independent of hemodynamic
state.”1
The physiologic and clinical relevance
of the indexed internal geometric area as
used by these authors must, however, be
challenged. Indeed, it has never been
shown that this parameter can be related, in
any significant manner, to transvalvular
pressure gradients; in particular, it has been
demonstrated that the indexed internal geo-
metric orifice area cannot be used to predict
which patients will have high postoperative
3gradients. Inherent to the pathophysiology
1852 The Journal of Thoracic and Cardiovof valve PPM is the concept that too small
a prosthesis in too large a patient will pro-
duce abnormally high gradients and thus
have potentially detrimental consequences
such as might occur with a native aortic
stenosis. Thus if the indexed internal geo-
metric area cannot be related to postoper-
ative gradients, we do not see how it can
logically be used to identify PPM or to
characterize its severity.
In contrast, and despite its inherent lim-
itations, the indexed effective orifice area is
the only parameter that has consistently
been shown to correlate with postoperative
gradients, as well as being highly predic-
tive of adverse outcomes.3-5 Indeed, when
the definition of PPM is based on this pa-
rameter, the phenomenon has been shown
to be highly prevalent (19%-70%, depend-
ing on series4,5) and to be associated with
less symptomatic improvement, worse he-
modynamics at rest and during exercise,
less regression of left ventricular hypertro-
phy, and more cardiac events after opera-
tion.4,5 A recent report from our own lab-
oratory has clearly shown that PPM has a
major impact on early mortality, particu-
larly in patients with poor left ventricular
function and that, in contrast to other risk
factors, it can easily be prevented by use of
a simple strategy at the time of operation.5
Such a strategy was recently used by Cas-
tro and associates6; as a result, the inci-
dence of moderate-severe PPM in their
population was only 2.5%, instead of the
17% that would have occurred had this
prospective strategy not been used,
whereas operative mortality remained low
(1%). Extrapolating these findings to the
total number of aortic valve replacements
being performed each year in North Amer-
ica, it is estimated that approximately 1000
operative deaths could potentially be
avoided through use of such a strategy.
In this context, the conclusion of these
two articles with regard to the prevalence
of PPM and its consequences cannot be
accepted at face value, because the param-
eter used to define PPM is not valid to
characterize postoperative hemodynam-
ics.3 To the contrary, we still believe in the
“value of concentrating on better hemody-
namic performance”1 and that research
aimed at properly identifying PPM, as well
as preventing it, can significantly contrib-
ute to improved outcomes after aortic valve
surgery.
ascular Surgery ● June 2004Jean G. Dumesnil, MD, FRCPC, FACC
Philippe Pibarot, DVM, PhD, FACC
Research Center of Laval Hospital/Quebec
Heart Institute
Laval University
Sainte-Foy, Quebec, Canada
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Reply to the Editor:
We have long respected the excellent and
prolific work of Dumesnil and Pibarot, so it
is not surprising that we referred to their
publications in our articles. However, they
are unhappy in part with the way we have
interpreted (or misinterpreted) their
work,1,2 and in part with the surgical rec-
ommendations we based on survival data
from our multicenter meta-analysis,1 which
differ from their own, which were based
largely on functional prosthesis perfor-
mance data.
What We Studied
Survival
We studied the relation of geometric pros-
thesis size to time-related survival with
nine sources of data and nearly 70,000 pa-
tient-years of follow-up among 13,258 pa-
tients who underwent aortic valve replace-
ment with mechanical prostheses, stent-
Letters to the Editormounted bioprostheses, and allografts at
multiple institutions on two continents.1
Long-term survival is a relevant and
important goal of aortic valve replace-
ment,3 although how it is associated with
efficiency of prosthetic devices remains
controversial. Use of small label-size pros-
theses has been presumed by many sur-
geons to reduce survival after valve re-
placement. When patients were stratified
by label size in our large study, however,
prosthesis size was found to have little im-
pact on survival (in contrast to substantial
impact of patient factors, such as age). Un-
like all previous studies, ours had the sta-
tistical power to detect even small differ-
ences in survival, with 1109 prostheses of
label size 19 mm or smaller and 2984 of
label size 21 mm.
To increase sensitivity, we focused our
survival analysis on the geometric dimen-
sion of the internal orifice of the prosthesis
normalized to patient size (prosthesis-pa-
tient size), a concept familiar in congenital
heart disease but less so in adult heart dis-
ease.4 Stratifying patients by prosthesis-
patient size revealed no impact on long-
term or intermediate survival. However, in
risk-adjusted and balancing score–adjusted
analyses, when geometric orifice size was
less than about the lower 95% confidence
limit for normal human aortic valve size,
which is uncommon in prudent aortic valve
replacement (only 85 patients had prosthe-
sis-patient size smaller than 0.85 cm2/m2),
early survival was affected to a small ex-
tent (1% to 2%).
Adjusting Prosthesis-Patient Size
for Prosthesis Model
Physics of blood flow dictates that as pros-
thesis geometric orifice size decreases, en-
ergy loss at a given flow rate increases.
However, inertia, turbulence, other distur-
bances of blood flow velocity profile, and
many other factors also affect energy loss.
Therefore, as described in the multi-insti-
tutional article,1 we searched for a relation
of prosthesis-patient size to survival that
was specific for each model of prosthesis
by means of interaction terms. We found
none of these to be statistically significant,
indicating similarity of the relationship of
geometric prosthesis-patient size to sur-
vival.
ThSurgical Inferences
Surgical inferences drawn concerning pros-
thesis size selection were based on survival
data within the context of prudent valve
replacement in these numerous representa-
tive institutions. We had no functional
prosthesis performance data after operation
for these patients, which might have further
increased sensitivity of the survival analy-
sis, thereby further refining prognosis and
possibly surgical recommendations.
What We Did Not Study
Contrary to the letter, we did not study
“postoperative outcomes” in general. We
focused on one end point only: time-related
mortality from any cause after aortic valve
replacement. It is possible that either geo-
metric or functional prosthesis-patient size
might be more strongly related to other end
points—such as sudden death, death in
heart failure, or various measures of quality
of life—that do not translate into a detect-
able survival difference.
We also studiously avoided the term
prosthesis-patient mismatch. No doubt a
clinical syndrome of prosthesis-patient
mismatch occurs, as described by Rahim-
toola5 and Rahimtoola and Murphy.6 How-
ever, through the years its definition has
ceased being a clinical diagnosis and has
become arbitrarily inferred from postoper-
ative echocardiographic velocity measure-
ments. We had no postoperative echocar-
diographic data in the assembled databases
to address this issue, so we cannot discuss
it further.
Alternative Proposal
Functional Projected Orifice Size
More interesting is the alternative proposed
by Dumesnil and Pibarot: that rather than
geometric orifice size, we should use func-
tional projected orifice size.7 They claim
that projected size is more highly corre-
lated with pressure gradient across a pros-
thesis than is geometric size.8 Thus, logi-
cally, it should be more sensitive to
differences in time-related survival. This
might be the case.
Prerequisites
Before accepting this alternative, several
things need to be in place and clarified. Just
as we had available an equation relating
patient size to normal aortic valve size de-
rived from 6801 measurements,9 so we
need an equation relating patient size to
e Journal of Thoracic and Cardiovascular Sfunctional prosthesis size that is based on a
substantial number of measurements. For
this, high-quality individual patient postop-
erative Doppler velocity data for each label
size of current aortic valve prostheses
would need to be assembled, along with
height and weight, and an appropriate anal-
ysis would need to be performed to obtain
the equation. However, accurate (unbi-
ased), precise (reproducible), and extensive
(power) functional estimates of prosthesis
size are elusive. They are related to many
patient characteristics, left ventricular out-
flow complex factors, time, measurement
variability, interobserver variability,
method of computation, and myriad other
factors. It is sobering that even in vitro
laboratory estimates of hemodynamic
properties of prostheses are fraught with
important institutional variation (as much
as 200% to 400%)!10 Thus, it is likely that
the in vivo relation will have substantial
scatter. Then an association should be
sought between survival and functional
prosthesis-patient size, with reference to
the normalizations suggested in the arti-
cles.1,2
Two Notes of Caution
Correlation Between Variables
Derived From the Same Data
One premise of the letter is that transpros-
thesis pressure gradients are more closely
correlated with functional prosthesis size
than with geometric prosthesis size (and
implicitly that pressure gradient is related
to survival).8 It is not appreciated in such
comparisons that the same Doppler veloc-
ities are used to compute both pressure
gradient and functional prosthesis size.
This guarantees a close correlation between
the two; they are not independent measure-
ments! This obligatory correlation leads
Dumesnil and Pibarot to state that “indexed
internal geometric orifice area cannot be
used to predict which patients will have
high postoperative gradients.” This is, in
our opinion, stretching the statistics.
Avoiding 1000 Deaths per Year
The second note of caution is the notion
that if a policy of liberal aortic root en-
largement accompanying aortic valve re-
placement were adopted, then “each year
in North America...approximately 1000
operative deaths could potentially be
avoided.” This too is a stretch of statistics.
urgery ● Volume 127, Number 6 1853
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colleagues’ observation11 of a single death
among 114 patients (70% confidence limits
0.1%-3.0% mortality) in the concurrent set-
ting of 543 patients deemed not in need of
aortic root enlargement; the latter sustained
a mortality of 4.1% with 70% confidence
limits of 3.2% to 5.1%.11 These confidence
limits and the context caution against con-
cluding that widespread application of the
proposed algorithm is likely to lower oper-
ative mortality.
Small sets of data pose two dangers,
identifying spurious relations in small sub-
groups and failing to identify relations be-
cause of lack of statistical power. These
concerns motivated collaborators in the
multi-institutional study to contribute more
than 13,000 patients with 70,000 patient
years of follow-up.
Disclaimer
In responding to this letter, we must ac-
knowledge that we reside within the insti-
tution with the highest volume of heart
valve operations on the North American
continent. The practice at The Cleveland
Clinic Foundation has not been to avoid
using small-sized prostheses in small aortic
roots. Yet hospital mortality for 881 pri-
mary isolated aortic valve replacements in
the last 5 years was 1.2%, and for 996
primary combined aortic valve replace-
ments with coronary artery bypass grafting
it was 2.0%. In some instances, left ven-
tricular outflow tract myectomy is per-
formed for obstruction at that level, but
rarely is aortic root enlargement per-
formed.
We remain interested in performance of
prostheses, but we believe that available
evidence suggests that other factors have
more impact on long-term all-cause mor-
tality than does prosthesis-patient size,
however expressed.
Eugene H. Blackstone, MD
A. Marc Gillinov, MD
Delos M. Cosgrove, MD
Department of Thoracic and Cardiovascular
Surgery
The Cleveland Clinic Foundation
Cleveland, OH 44195
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Epidemiologic contrast of predictors’
trends for outcomes of coronary
artery bypass grafting: Heart failure
versus ventricular function versus
left main disease
To the Editor:
I read with interest the article by Davier-
wala and colleagues1 in the November
2003 issue of the Journal. The work ana-
lyzed differential change in predictors of in
hospital mortality after coronary artery by-
pass grafting. The study elegantly demon-
strated the diminishing statistical signifi-
cance for left ventricular function greater
than 20% as a predictor for mortality dur-
ing a 12-year period. Several explanations
are provided related to patient comorbidity,
interventional cardiology, surgeon experi-
ence, and intensive patient care. It is well
ascular Surgery ● June 2004established that one of the major determi-
nants of morbidity during and after coro-
nary artery bypass grafting is low left ven-
tricular ejection fraction.2 The results of
numerous coronary artery bypass grafting
trials performed in the 1970s and 1980s
show that despite this increased morbidity,
the benefits of this procedure for patients
with multivessel coronary artery disease
and low left ventricular systolic function in
many cases outweigh the risks.3 The article
does not contain data for the actual causes
of death in this large group of patients,
which would be epidemiologically rele-
vant. Given the data provided, however, it
is difficult to observe a contrast in the
trends between congestive heart failure
(CHF) and left ventricular function as pre-
dictor variables. Davierwala and col-
leagues1 also stated in their discussion that
from studying the data again in Table 1 it is
clear to the reader that CHF held an in-
creasing proportion as morbidity in the pa-
tient cohort (7.8% vs 9.4% vs 9.4%) during
the interval (1990-1993 vs 1994-1997 vs
1998-2001). Moreover, according to the
original article’s Table 3, after a multivar-
iate analysis CHF showed an increasing
trend for odds ratio by year group (1.9 vs
3.6).1 Given this contrast of predictor out-
come trends, the authors should have in-
cluded other explanations. In simple terms,
the CHF increasing trend could reflect an
increase in diastolic heart failure, assuming
that the proportions of new patients in each
time interval were significant. In other
words, the decline of the predictor value in
left ventricular dysfunction was not related
to interyear group patient death. The au-
thors stated that left main disease in a
“somewhat counterintuitive finding” was
“unmasked” in the last time cohort, with an
odds ratio of 1.7 in Table 3 of the original
article.1 From their data, both CHF and left
main disease increased in prevalence, yet
worsening ventricular dysfunction de-
clined. This constellation may reflect a
change in the ventricular dysfunction func-
tion from systolic to diastolic biometri-
cally.
Furthermore, the typical risk factors and
comorbidities of female gender, diabetes,
and hypertension together increased signif-
icantly during the entire period of their
study. This association has now been found
to be the same with diastolic dysfunction.4
As we know now, there is growing appre-
ciation of diastolic heart failure as a distinct
